ホーム › 乳がん › カリフォルニア州 › Mountain View
Mountain View、CAにおける乳がんの臨床試験
Mountain Viewとその周辺地域（約30マイル以内）の拠点で、乳がんに関する26件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Stanford Women's Cancer Center, Palo Alto · 5マイル先
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- Stanford University School of Medicine, Palo Alto · 5マイル先
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- El Camino Hospital, Mountain View
- Palo Alto Medical Foundation, Mountain View
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
被験者募集中第1/2相
- Stanford Medicine Cancer Center, Stanford · 5マイル先
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
被験者募集中第3相
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Stanford University Medical Center, Stanford · 5マイル先
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Stanford University Medical Center, Stanford · 5マイル先
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Stanford Cancer Center, Palo Alto · 5マイル先
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
被験者募集中第3相
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto · 5マイル先
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Stanford Women's Cancer Center, Palo Alto · 5マイル先
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
被験者募集中第1相
- Stanford University Hospital, Stanford · 5マイル先
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
被験者募集中第3相
- Research Site, Palo Alto · 5マイル先
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
被験者募集中第2相
- Stanford Cancer Institute, Palo Alto · 5マイル先
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Palo Alto Medical Foundation Research Center, Palo Alto · 5マイル先
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5マイル先
- 他1件
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
被験者募集中第2相
- Stanford University, Stanford · 5マイル先
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
被験者募集中第2/3相
- Local Institution - 0358, Stanford · 5マイル先
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto · 5マイル先
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
被験者募集中第1相
- Stanford University Medical Center, Palo Alto · 5マイル先
Magnetic Resonance Imaging of Breast Cancer
被験者募集中健康なボランティア歓迎
- Stanford University School of Medicine, Stanford · 5マイル先
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
被験者募集中観察研究
- Stanford University School of Medicine, Stanford · 5マイル先
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5マイル先
- Stanford Cancer Institute Palo Alto, Palo Alto · 5マイル先
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
被験者募集中第1相
- Stanford Cancer Institute, Stanford · 5マイル先
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
被験者募集中
- Stanford University, Stanford · 5マイル先
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
被験者募集中観察研究
- Stanford Cancer Institute, Palo Alto · 5マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Stanford · 5マイル先
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Mountain Viewにおける他の研究
- がん（全種類）40件の研究
- 転移性癌25件の研究
- 非小細胞肺癌21件の研究
- 急性骨髄性白血病19件の研究
- 卵巣がん19件の研究
- 自閉スペクトラム症17件の研究
- 肺がん17件の研究
- 前立腺がん15件の研究
- 心不全15件の研究
- 自閉症13件の研究
- 急性リンパ性白血病13件の研究
- 大腸癌13件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。